4/27
08:27 am
kymr
Infinimmune Appoints Anthony Slavin, Ph.D., as Senior Vice President of Portfolio Strategy [Yahoo! Finance]
Low
Report
Infinimmune Appoints Anthony Slavin, Ph.D., as Senior Vice President of Portfolio Strategy [Yahoo! Finance]
4/26
06:23 pm
kymr
A Look At Kymera Therapeutics (KYMR) Valuation After Fast Track News And Gilead Collaboration Progress [Yahoo! Finance]
Medium
Report
A Look At Kymera Therapeutics (KYMR) Valuation After Fast Track News And Gilead Collaboration Progress [Yahoo! Finance]
4/24
09:51 am
kymr
FDA Grants Fast Track Designation to Kymera Therapeutics, Inc. (KYMR)'s KT-621 for Eosinophilic Asthma [Yahoo! Finance]
Low
Report
FDA Grants Fast Track Designation to Kymera Therapeutics, Inc. (KYMR)'s KT-621 for Eosinophilic Asthma [Yahoo! Finance]
4/23
07:00 am
kymr
Kymera Therapeutics to Report First Quarter 2026 Financial Results on April 30, 2026
Low
Report
Kymera Therapeutics to Report First Quarter 2026 Financial Results on April 30, 2026
4/13
07:00 am
kymr
Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma
Medium
Report
Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma
4/9
07:00 am
kymr
Kymera Therapeutics Announces Gilead Sciences’ Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate
Medium
Report
Kymera Therapeutics Announces Gilead Sciences’ Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate
3/29
08:38 pm
kymr
Does Positive KT-621 Atopic Dermatitis Data Change The Bull Case For Kymera Therapeutics (KYMR)? [Yahoo! Finance]
Low
Report
Does Positive KT-621 Atopic Dermatitis Data Change The Bull Case For Kymera Therapeutics (KYMR)? [Yahoo! Finance]
3/28
11:12 am
kymr
Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting [Yahoo! Finance]
Low
Report
Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting [Yahoo! Finance]
3/28
11:00 am
kymr
Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting
Low
Report
Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting
3/16
10:58 am
kymr
Kymera Therapeutics (KYMR) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating on the stock.
Low
Report
Kymera Therapeutics (KYMR) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating on the stock.
3/14
05:36 pm
kymr
Kymera Trials IRF5 And STAT6 Degraders As Market Weighs Long Term Upside [Yahoo! Finance]
Low
Report
Kymera Trials IRF5 And STAT6 Degraders As Market Weighs Long Term Upside [Yahoo! Finance]
3/12
01:21 pm
kymr
Kymera Therapeutics, Inc. (KYMR) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]
Low
Report
Kymera Therapeutics, Inc. (KYMR) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]
3/10
07:08 am
kymr
Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting [Yahoo! Finance]
Low
Report
Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting [Yahoo! Finance]
3/10
07:00 am
kymr
Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting
Low
Report
Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting
3/9
10:47 pm
kymr
Kymera CEO Nello Mainolfi's Boldest Line Had Nothing to Do With the Earnings Miss [Yahoo! Finance]
Low
Report
Kymera CEO Nello Mainolfi's Boldest Line Had Nothing to Do With the Earnings Miss [Yahoo! Finance]
3/7
02:59 am
kymr
Low
Report
3/3
02:22 pm
kymr
Kymera Therapeutics (KYMR) had its price target raised by UBS Group AG from $90.00 to $128.00. They now have a "buy" rating on the stock.
Low
Report
Kymera Therapeutics (KYMR) had its price target raised by UBS Group AG from $90.00 to $128.00. They now have a "buy" rating on the stock.
3/2
01:53 pm
kymr
Kymera Therapeutics (KYMR) had its price target raised by Citigroup Inc. from $110.00 to $120.00. They now have a "buy" rating on the stock.
Low
Report
Kymera Therapeutics (KYMR) had its price target raised by Citigroup Inc. from $110.00 to $120.00. They now have a "buy" rating on the stock.
3/2
09:27 am
kymr
Kymera Therapeutics (KYMR) had its price target raised by Stephens from $95.00 to $100.00. They now have an "overweight" rating on the stock.
Low
Report
Kymera Therapeutics (KYMR) had its price target raised by Stephens from $95.00 to $100.00. They now have an "overweight" rating on the stock.
2/28
03:42 pm
kymr
The Bull Case For Kymera Therapeutics (KYMR) Could Change Following Wider Losses And Major Equity Plans [Yahoo! Finance]
Low
Report
The Bull Case For Kymera Therapeutics (KYMR) Could Change Following Wider Losses And Major Equity Plans [Yahoo! Finance]
2/28
01:40 pm
kymr
Kymera Therapeutics Pivots to Immunology, Highlights KT-621 Data, Starts IRF5 Dosing; Runway to 2029 [Yahoo! Finance]
Low
Report
Kymera Therapeutics Pivots to Immunology, Highlights KT-621 Data, Starts IRF5 Dosing; Runway to 2029 [Yahoo! Finance]
2/27
09:16 am
kymr
Kymera Therapeutics price target raised to $140 from $125 at Piper Sandler [Yahoo! Finance]
Medium
Report
Kymera Therapeutics price target raised to $140 from $125 at Piper Sandler [Yahoo! Finance]
2/26
05:33 pm
kymr
Kymera Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
Medium
Report
Kymera Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
2/26
05:03 pm
kymr
Kymera Therapeutics (KYMR) had its "overweight" rating reaffirmed by Morgan Stanley.
Medium
Report
Kymera Therapeutics (KYMR) had its "overweight" rating reaffirmed by Morgan Stanley.
2/26
02:11 pm
kymr
Kymera Therapeutics (KYMR) had its "outperform" rating reaffirmed by Royal Bank Of Canada.
Medium
Report
Kymera Therapeutics (KYMR) had its "outperform" rating reaffirmed by Royal Bank Of Canada.